RCS - Allergy Therapeutics - Allergy Therapeutics shares key findings at EAACI

Allergy TherapeuticsAnnouncement

09/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230609:nRSI1775Ca&default-theme=true

RNS Number : 1775C  Allergy Therapeutics PLC  09 June 2023

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Allergy Therapeutics shares key scientific findings from innovative research
portfolio at Congress of the European Academy of Allergy and Clinical
Immunology (EAACI) 2023

 

9 June 2023 Allergy Therapeutics (AIM: AGY), the fully integrated specialty
pharmaceutical company specialising in allergy immunotherapy, today announces
that the Group will be sharing key scientific findings from across its
research portfolio at the upcoming European Academy of Allergy and Clinical
Immunology (EAACI) Hybrid Congress, taking place from today until 11 June 2023
in Hamburg, Germany.

 

The EAACI Congress is the world's largest scientific conference specialising
in the field of allergy and clinical immunology and the flagship meeting of
the European Academy of Allergy and Clinical Immunology, an association of
more than 12,000 clinicians, researchers, and allied health professionals,
dedicated to improving the health of people affected by allergic diseases.

 

Among its nine posters being presented, Allergy Therapeutics will share:

·      Further clinical and preclinical studies on biomarker strategies,
patient responses and the mechanism of action of allergy immunotherapies. Part
of the data is derived from the positive G309 exploratory field study which
evaluated the efficacy and safety of Grass MATA MPL, the Group's short-course
subcutaneous allergen-specific immunotherapy (SCIT) candidate to address the
cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. These
findings supported the design of the ongoing pivotal Phase III Grass MATA MPL
G306 trial, which is on track to report interim topline safety & efficacy
data in Q4 2023.

·      Further pre-clinical data characterising the mechanism of action
of the Group's novel virus-like particle (VLP) based peanut allergy vaccine
candidate ("VLP Peanut"), which is currently being investigated in the Phase I
PROTECT trial with plans on track for data later in 2023.

·      Preclinical studies examining allergenic venom homology, an area
in which the Group is currently commercially active.

 

Allergy Therapeutics will also be hosting a hybrid symposium, "SCIT;
pioneering a new era", on Saturday 10 June, 14:30-15:30 CEST, chaired by
Professor Dr. med. Ludger Klimek, Head of the Centre for Rhinology and
Allergology, Wiesbaden, Germany. The symposium will consist of three
presentations covering the topics of venom immunotherapy, biomarker strategies
in allergy immunotherapy and an analysis of the VLP Peanut PROTECT study,
further exploring how the trial's study design bridges the pre-clinical and
clinical boundaries.

 

Results from the completed G309 exploratory field trial, investigating Grass
MATA MPL, the Group's short-course subcutaneous allergen-specific
immunotherapy (SCIT) candidate, have been accepted for upcoming publication in
the official journal of the EAACI, Allergy. During the EAACI congress on
Sunday 11 June at 15:00 - 15:30 CEST, Professor Mohamed Shamji, Reader in
Immunology & Allergy at Imperial College London, will give an overview of
this recently accepted publication titled "Short-course subcutaneous
pre-seasonal treatment with a 13-grass pollen allergoid reduces allergy
symptoms and relief medication use in allergic rhinitis: A randomised,
double-blind, placebo-controlled adaptive trial". This session will be in Hall
Y 7 on Level 2 during the SY 19 - Cutting Edge in Allergy, Asthma and
Immunology session.

 

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, commented: "We
are excited to be participating in this year's EAACI congress, joining
like-minded scientists and industry professionals, united in one mission - to
improve the lives of people living with allergies. With two innovative
short-course allergy immunotherapies currently in the clinic, Allergy
Therapeutics is delivering on its commitment to develop the next generation of
allergy immunotherapies with the potential to transform patients' lives. The
Phase III trial of our short-course grass pollen immunotherapy candidate,
Grass MATA MPL, and the Phase I PROTECT trial of our peanut allergy vaccine
candidate, VLP Peanut, are currently underway and we are looking forward to
sharing further insights with the community on these potentially
transformative allergy therapies."

 

The complete list of Allergy Therapeutics-sponsored abstracts accepted by
EAACI for presentation are available on the Group's website.

 

No new material price sensitive information is expected to be disclosed on
Allergy Therapeutics at the EAACI Congress 2023.

 

 

 Allergy Therapeutics' Hybrid Symposium

 SCIT; pioneering a new era

 Saturday 10 June 2023; 14:30-15:30 (CEST)
 Introduction                                                                     Introduction

 Chair: Professor Dr. med. Ludger Klimek, Head of the Centre for Rhinology and
 Allergology, Wiesbaden, Germany
 Speaker                                                                          Venom Immunotherapy: Efficacy led by quality

 Dr. Arantza Vega Castro, Chief of the Allergy Department - Guadalajara
 University Hospital. Associated Professor - International University of
 Catalonia. Chair of the EAACI insect venom hypersensitivity working group

 Speaker:                                                                         Biomarker Strategies in AIT: A primer for the practitioner

 Dr. Janice A Layhadi, Immunomodulation and Tolerance Group, Allergy and
 Clinical Immunology, Department of National Heart and Lung Institute, Imperial
 College London, London, UK
 Speaker:                                                                         VLP Peanut PROTECT Study: bridging the preclinical-clinical boundaries

 Prof. Dr. Martin Bachmann, Head of the Department of Immunology, University of
 Bern, Switzerland and Professor of Immunology, University of Oxford, Nuffield
 Department of Medicine
 All speakers                                                                     Q&A

 

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAPKPESPDEFA